IP Library › Granted Patent US 12,239,622
Granted Patent B2
US 12,239,622 · App. 17/255,887 · Granted Mar 4, 2025

Compositions comprising amino acids for use in the prevention and treatment of liver diseases

Inventor: Paolo Luca Maria Giorgetti (Milan, IT)
Assignee: PROFESSIONAL DIETETICS S.P.A.
A61K31/198A61K9/0053A61K31/194A61K47/22A61P1/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,239,622
App. No.
17/255,887
Granted
Mar 4, 2025
Kind
B2
Abstract

Composition for use in the prevention and/or treatment of a liver disease in a mammal, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and the carboxylic acids citric acid, succinic acid, malic acid.

Claims (20)

1. A method of treating liver cirrhosis, alcoholic liver disease (ALD) or non-alcoholic fatty liver disease (NAFLD), comprising administering to a subject in need thereof a therapeutic amount of a composition, wherein the composition comprises an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and the carboxylic acids citric acid, succinic acid, malic acid.

2. The method according to claim 1 , wherein the active agent comprises an overall amount of citric acid, malic acid and succinic acid and an overall amount of leucine, isoleucine, valine, lysine and threonine, wherein the weight ratio between the overall amount of citric acid, malic acid and succinic acid and the overall amount of leucine, isoleucine, valine, lysine and threonine is between 0.05 and 0.3.

3. The method according to claim 1 , wherein the active agent comprises an overall amount of citric acid, malic acid and succinic acid and an overall amount of leucine, isoleucine and valine, wherein the weight ratio between the overall amount of citric acid, malic acid and succinic acid and the overall amount of leucine, isoleucine and valine is between 0.1 and 0.4.

4. The method according to claim 1 , wherein the active agent comprises a weight ratio between citric acid and the sum of malic acid and succinic acid is between 1.0 and 4.0.

5. The method according to claim 1 , wherein the active agent comprises a weight ratio of citric acid:malic acid:succinic acid between 10:1:1 and 2:1.5:1.5.

6. The method according to claim 1 , wherein said active agent further comprises at least one amino acid selected from the group consisting of histidine, phenylalanine, methionine, tryptophan, tyrosine and cysteine.

7. The method according to claim 1 , wherein said active agent further comprises histidine, phenylalanine, methionine, tryptophan and cysteine.

8. The method according to claim 1 , wherein the active agent comprises an overall molar amount of citric acid, malic acid and succinic acid and an overall molar amount of methionine, phenylalanine, histidine and tryptophan, wherein the ratio between the overall molar amount of citric acid, malic acid and succinic acid and the overall molar amount of methionine, phenylalanine, histidine and tryptophan is higher than 1.35.

9. The method according to claim 1 , wherein the active agent comprises an overall molar amount of the three carboxylic acids citric acid, succinic acid and malic acid and an overall molar amount of lysine and threonine, wherein the ratio between the overall molar amount of the three carboxylic acids citric acid, succinic acid and malic acid and the overall molar amount of lysine and threonine is between 0.10 and 0.70.

10. The method according to claim 1 , wherein the active agent comprises a weight or molar amount of citric acid, an overall weight or molar amount of malic acid and succinic acid, wherein the weight or molar amount of citric acid is higher than the overall weight or molar amount of malic acid and succinic acid.

11. The method according to claim 1 , wherein the active agent comprises a weight ratio between leucine and citric acid between 5 and 1.

12. The method according to claim 1 , wherein the composition further comprises one or more vitamins.

13. The method according to claim 2 , wherein the weight ratio between the overall amount of citric acid, malic acid and succinic acid and the overall amount of leucine, isoleucine, valine, lysine and threonine is between 0.1 and 0.25.

14. The method according to claim 3 , wherein the weight ratio between the overall amount of citric acid, malic acid and succinic acid and the overall amount of leucine, isoleucine and valine is between 0.15 and 0.35.

15. The method according to claim 4 , wherein the active agent comprises a weight ratio between citric acid and the sum of malic acid and succinic acid between 1.5 and 2.5.

16. The method according to claim 5 , wherein the active agent comprises a weight ratio of citric acid:malic acid:succinic acid between 7:1:1 and 1.5:1:1.

17. The method according to claim 5 , wherein the active agent comprises a weight ratio of citric acid:malic acid:succinic acid between 5:1:1 and 3:1:1.

18. The method according to claim 7 , wherein said active agent further comprises tyrosine.

19. The method according to claim 9 , wherein the ratio between the overall molar amount of the three carboxylic acids citric acid, succinic acid and malic acid and the overall molar amount of lysine and threonine is between 0.15 and 0.55.

20. The method according to claim 11 , wherein the active agent comprises a weight ratio between leucine and citric acid between 2.50 and 3.50.

Assignments (2)
MERGER Recorded May 17, 2022
From: PROFESSIONAL DIETETICS INTERNATIONAL S.R.L.
To: PROFESSIONAL DIETETICS S.P.A.
Reel/Frame 059932/0940 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2020
From: GIORGETTI, PAOLO LUCA MARIA
To: PROFESSIONAL DIETETICS INTERNATIONAL S.R.L.
Reel/Frame 054742/0681 →
Priority Claims (1)
IT 102018000006725 · Jun 27, 2018 · national
Continuity (1)
Related Publication 20210260011A1 · Aug 26, 2021
References Cited (80)
US 6537969B1 · Blass · 2003 [cited by examiner]
US 7982066B2 · Scheele · 2011 [cited by applicant]
US 9597367B2 · Wolfe et al. · 2017 [cited by applicant]
US 10226441B2 · Higashi et al. · 2019 [cited by applicant]
US 11337946B2 · Giorgetti · 2022 [cited by applicant]
US 11452702B2 · Giorgetti · 2022 [cited by applicant]
US 11957651B2 · Giorgetti · 2024 [cited by applicant]
US 20030013761A1 · Joshi et al. · 2003 [cited by applicant]
US 20030055099A1 · Martynyuk et al. · 2003 [cited by applicant]
US 20130084378A1 · Jun et al. · 2013 [cited by applicant]
US 20130237605A1 · Zemel et al. · 2013 [cited by applicant]
US 20140315788A1 · Wolfe et al. · 2014 [cited by applicant]
US 20160038565A1 · Khan · 2016 [cited by applicant]
US 20180000764A1 · Hernández Miramontes · 2018 [cited by applicant]
US 20200230093A1 · Giorgetti · 2020 [cited by applicant]
US 20200253906A1 · Giorgetti · 2020 [cited by applicant]
US 20210260011A1 · Giorgetti · 2021 [cited by applicant]
US 20220110899A1 · Giorgetti · 2022 [cited by applicant]
US 20220249418A1 · Giorgetti · 2022 [cited by applicant]
US 20230067642A1 · Giorgetti · 2023 [cited by applicant]
US 20230079527A1 · Giorgetti · 2023 [cited by applicant]
CA 2972889A1 · 2016 [cited by applicant]
EP 2196203B1 · 2012 [cited by applicant]
EP 2676664A1 · 2013 [cited by applicant]
EP 2881112B1 · 2019 [cited by applicant]
JP 2007161642A · 2007 [cited by applicant]
JP 6023813B2 · 2016 [cited by examiner]
WO 2001051047A1 · 2001 [cited by applicant]
WO 2003013487A2 · 2003 [cited by applicant]
WO 2005034932A2 · 2005 [cited by applicant]
WO 2007049818A1 · 2007 [cited by applicant]
WO 2012147901A1 · 2012 [cited by applicant]
WO 2016093104A1 · 2016 [cited by applicant]
WO 2016181335A1 · 2016 [cited by applicant]
WO WO2016179657A1 · 2016 [cited by examiner]
WO 2017020121A1 · 2017 [cited by applicant]
WO 2017089612A1 · 2017 [cited by applicant]
WO 2018201024A1 · 2018 [cited by applicant]
WO 2019021135A1 · 2019 [cited by applicant]
WO 2019021137A · 2019 [cited by applicant]
WO 2019070750A1 · 2019 [cited by applicant]
WO 2020003013A1 · 2020 [cited by applicant]
WO 2022266480 · 2022 [cited by applicant]
Daher et al., J Clin Transl Hepatol. Mar. 28, 2018;6(1):69-78 (Year: 2018). [cited by examiner]
Tapper et al., JAMA. 2023;329(18):1589-1602 (Year: 2023). [cited by examiner]
Park Dong et al. (JP-6023813-B2, 2016, English Translation, pp. 1-16 (Year: 2016). [cited by examiner]
MP Biomedical—Technical Information—AIN-93-Diet,pp. 1-3 (Year: 2023). [cited by examiner]
Noguchi et al. WO/2007/049818 published Mar. 5, 2007, English Translation pp. 1-10 (Year: 2007). [cited by examiner]
Tedesco et al.; “A specific amino acid formula prevents alcoholic liver disease in rodents”; Jan. 25, 2018; Am. J. Gastrointest. Liver Physiol.; 314: G566-G582; doi: 10.1152/ajpgi.00231.2017 (Year: 2018). [cited by examiner]
Nergiz et al.; “Organic acid content and composition of the olive fruits during ripening and its relationship with oil and sugar”; 2009; Scientia Horticulturae; 122: 216-220 (Year: 2009). [cited by examiner]
International Search Report and Written Opinion of the ISA for PCT/IB2019/052694 mailed Jun. 25, 2019, 11 pages. [cited by applicant]
Database WPI Week 200744, May 3, 2007, Thomson Scientific, London, GB, XP002788927, 3 pages. [cited by applicant]
Tedeco et al., A specific amino acid formula prevents alcoholic liver disease in rodents, Am J Physiol Gastrointest Liver Physiol ., Epub Jan. 25, 2018, 314(5):G566-G582. [cited by applicant]
Brocca, I., et al., “Proteomic analysis of plasma after branched chain enriched mixture supplementation in mice”, Journal of the International Society of Sports Nutrition, vol. 10, No. 1, Apr. 3, 2013, 5 pages. [cited by applicant]
International Search Report and Written Opinion of the ISA for PCT/182018/055425 mailed Nov. 2, 2018, 17 pages. [cited by applicant]
Bournat, J.C., et al., Mitochondrial Dysfunction in Obesity Current Opinion Endocrinol Obesity, Oct. 17, 2010, (5): 446-452. [cited by applicant]
Gorshinova et al., “Mitochondrial dysfunction as one of the mechanisms of impaired reproductive function in obesity.” Akusherstvo i ginekologiya/Obstetrics and Gynecology, 2014; 7: 9-13. [cited by applicant]
Non-Final Office Action issued in co-pending U.S. Appl. No. 16/634,330, mailed Jun. 30, 2021. [cited by applicant]
International Search Report for PCT/IB2018/055428, mailed Nov. 6, 2018, 5 pages. [cited by applicant]
Written Opinion of the ISA for PCT/IB2018/055428, mailed Nov. 6, 2018, 7 pages. [cited by applicant]
Restriction Requirement issued in co-pending U.S. Appl. No. 16/634,330, mailed May 6, 2021. [cited by applicant]
Abdullah, Chowdhury S. et al., “Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration”, Scientific Reports, vol. 9, No. 1, Feb. 14, 2019… [cited by applicant]
Chiechio, et al., “L-Acetylcarnitine: A Proposed Therapeutic Agent for Painful Peripheral Neuropathies”, Current Neuropharmacology, vol. 4, No. 3, Jul. 1, 2006, pp. 233-237 (5 pages). [cited by applicant]
Choudhury, Aaheli Roy et al., “Mitochondrial determinants of cancer health disparities”, Seminars in Cancer Biology, 47, 2017, pp. 125-146. [cited by applicant]
Damiani, Roberto Marques et al., “Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone”, Archives of Toxicology, vol. 90, No. 9, Jun. 25, 2016, pp. 2063-2076. [cited by applicant]
Gilliam, Laura A.A. et al., “The anticancer agent doxorubicin disrupts mitochondrial energy metabolism and redox balance in skeletal muscle”, Free Radical Biology and Medicine, vol. 65, Sep. 7, 2013, pp. 988-996. [cited by applicant]
Hall et al., “Lipid Peroxidation in Brain or Spinal Cord Mitochondria After Injury” J Bioenerg. Biomembr. Apr. 2016 ; 48(2): 169-174 (2017). [cited by applicant]
Hiensch, Anouk E. et al., “Doxorubicin-induced skeletal muscle atrophy: Elucidating the underlying molecular pathways”, Acta Physiologica, vol. 229, No. 2, Oct. 10, 2019, 18 pp. [cited by applicant]
International Search Report and Written Opinion of the ISA for PCT/IB2018/055425 mailed Nov. 2, 2018, 17 pages. [cited by applicant]
International Search Report and Written Opinion of the ISA for PCT/IB2020/051027 dated Apr. 29, 2020, 11 pages. [cited by applicant]
International Search Report and Written Opinion of the ISA for PCT/IB2020/062301 dated Mar. 1, 2021 (12 pages). [cited by applicant]
International Search Report dated Mar. 16, 2021, for PCT/IB2020/062291, 5 pp and Written Opinion of the International Searching Authority dated Mar. 16, 2021, for PCT/IB2020/062291, 8 pp. [cited by applicant]
Keenan et al,, “Effects of carboxylic acids on the uptake of non-transferrin-bound iron by astrocytes, Neurochemistry International”, 2010, 56: 843-849. [cited by applicant]
Nakagaichi, M., et al., “Effects of Exercise Training Plus Vespa Amino Acid Mixture (VAAM) Ingestion in Obese Women,” Japanese Journal of Health Promotion, 3, 11-16, 2001 with English Abstract. [cited by applicant]
Nakamura, E., et al., “Assessment of Biological Age by Principal Component Analysis,” Mechanisms of Ageing and Development, vol. 46. Issues1-3, pp. 1-18, 1988, with English Translation of Office Action for JP Applicatio… [cited by applicant]
Notice of Allowance mailed in U.S. Appl. No. 17/724,537 on Dec. 20, 2023. [cited by applicant]
Scholpa & Schnellmann, “Mitochondrial-Based Therapeutics for the Treatment of Spinal Cord Injury: Mitochondrial Biogenesis as a Potential Pharmacological Target.” J Pharmacol Exp Ther 363:303-313, Dec. 2017. [cited by applicant]
Wang, X. et al., “Increases in mitochondrial biogenesis impair carcinogenesis at multiple levels” Molecular Oncology, Elsevier. Jul. 27, 2011., vol. 5, No. 5, pp. 399-409 (11 pages). [cited by applicant]
Wang et al., “Mitochondrial dysfunction in neurodegenerative diseases and the potential countermeasure,” CNS Neurosci Ther. 25: 816-824 (2019). [cited by applicant]
Sullivan et al., “Mitochondrial Permeability Transition in CNS Trauma: Cause or Effect of Neuronal Cell Death?” Journal of Neuroscience Research, 2005, 79:231-239. [cited by applicant]
Cited By (3)
US 12,472,159 US 12,527,759 US 12,622,886